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Objective: Although aberrant interactions between gut
microbes and the intestinal immune system have been
implicated in this skin disease, the nature of the microbiome
dysfunction underlying the disease remains unclear.
Methods: The gut microbiome from 132 subjects, including 90
patients with AD, was analyzed by using 16S rRNA gene and
metagenome sequence analyses. Reference genomes from the
Human Microbiome Project and the KEGG Orthology database
were used for metagenome analyses. Short-chain fatty acids in
fecal samples were compared by using gas chromatographic–
mass spectrometric analyses.
Results: We show that enrichment of a subspecies of the major
gut species Faecalibacterium prausnitzii is strongly associated
with AD. In addition, the AD microbiome was enriched in genes
encoding the use of various nutrients that could be released
from damaged gut epithelium, reflecting a bloom of auxotrophic
bacteria. Fecal samples from patients with AD showed
decreased levels of butyrate and propionate, which have anti-
inflammatory effects. This is likely a consequence of an
intraspecies compositional change in F prausnitzii that reduces
the number of high butyrate and propionate producers,
including those related to the strain A2-165, a lack of which has
been implicated in patients with Crohn disease.
Conclusions: The data suggest that feedback interactions
between dysbiosis in F prausnitzii and dysregulation of gut
epithelial inflammationmight underlie the chronic progression of
AD by resulting in impairment of the gut epithelial barrier, which
ultimately leads to aberrant TH2-type immune responses to
allergens in the skin. (J Allergy Clin Immunol 2016;137:852-60.)
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852The chronic inflammatory, noncontagious, and pruritic skin
disorder atopic dermatitis (AD) affects up to 25% of children and
2% to 3% of adults in the United States.1 In general, the incidence
of atopic disorders has increased over the last few decades, espe-
cially in industrialized countries, suggesting that a modern life-
style is a major contributing factor to this global epidemic.1,2
The hygiene hypothesis states that reduced exposure to microbes
in early childhood affects the natural development of the immune
system or immune tolerance, resulting in an increased susceptibil-
ity to allergic diseases.3,4 Alternatively, the diet-microbiome
hypothesis emphasizes that changes in the westernized diet
reflecting a lower intake of fiber might lead to changes in the
gut microbiome, followed by decreased production of immuno-
modulatory products, in particular short-chain fatty acids
(SCFAs), which have anti-inflammatory effects and contribute
to the maintenance of epithelial barrier function.5,6 The inflamed
epithelium with impaired barrier function has been associated
with various disorders, including atopic eczema, celiac disease,
and Crohn disease.7-9
Although the direct cause and pathophysiology of AD are
poorly defined, skin damage in patients with AD is likely caused
primarily by aberrant TH2-type immune responses, resulting in
overproduction of proinflammatory cytokines against common
environmental allergens.5,10,11 Concurrent dysbiosis in the skin
flora has been observed in association with AD, and such
changes include an increase in Staphylococcus aureus and a
decrease in the overall diversity of the microbial community.12
The results of decades of research suggest that imbalances in
certain gut bacterial species are associated with atopic disor-
ders.13,14 In addition, low microbial diversity in the microbiota
in the first month of life has been associated with subsequent in-
cidences of AD.15 Although these studies have stressed the sig-
nificance of dysbiosis in the gut microbiota in patients with
AD,14,16 the specific microbial dysfunction that adversely af-
fects the regulation of inflammation underlying AD remains
unknown.
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Study subjects and fecal sample collection
Ninety patients with AD were recruited for this research among the
outpatients of Korea University Anam Hospital in Seoul, Korea, who came
from various parts of Seoul, a city of more than 10 million residents, and 42
subjects without AD were chosen from volunteers from the same area (see
Table E1 in this article’s Online Repository at www.jacionline.org). Patients
with AD were given a diagnosis based on the SCORAD scoring system, and
the control group (subjects without AD) was defined by a lack of history of
visible signs of skin damage indicative of AD. None of the subjects received
antibiotic treatment within 6 months before fecal sample collection. The
Ethics Committee of the Anam Hospital of Korea University approved this
study, and participants or their parents (in cases in which the participants
were <17 years old) provided written informed consent for the study. Fecal
samples of approximately 5 g were obtained from each subject and stored
at 2808C until DNA extraction.
DNA sample preparation
Fecal samples were ground in liquid nitrogen with a mortar and pestle, and
400 mg of each ground sample was transferred to 4 microcentrifuge tubes.
Five hundred microliters of a solution containing 0.1-mm-diameter zirconia/
silica beads (BioSpec Products, Bartlesville, Okla), 500 mL of extraction
buffer (200 mmol/LTris [pH 8.0], 200 mmol/L NaCl, and 20 mmol/L EDTA),
210 mL of 20% SDS, and 500 mL of phenol/chloroform/isoamyl alcohol
mixture (25:24:1, pH 7.9) was added to each tube. The bacterial content in the
samples was released by disrupting the cell envelope with a bead beater
(BioSpec products) for 2.5 minutes at room temperature. DNAwas extracted
from the supernatant with phenol/chloroform/isoamyl alcohol (25:24:1, pH
7.9) and precipitated with isopropanol. DNA pellets were dried and dissolved
in TE buffer (10 mmol/L Tris [pH 8.0] and 1 mmol/L EDTA), and the
concentration was adjusted to 100 ng/mL.Sequencing of the V1-V2 16S rRNA gene regions
A PCR reaction targeting the V1-V2 region of the 16S rRNA gene was
conducted with each DNA sample in a 25-mL reaction mixture containing 100
ng of template DNA, 5 mL of HotStarTaq PCR buffer (Qiagen, Germantown,
Md), 1 U of HotStarTaq DNA polymerase (Qiagen), and 0.4 mmol/L each of
forward and reverse primer. The forward primer, 59-CGTATCGCCTC
CCTCGCGCCATCAGNNNNNNNNTCAGAGTTTGATCCTGGCTCAG-39,
was a composite of the 454 Titanium adapter A (underlined nucleotides), a
unique 8-base barcode (shown with 8 Ns), a linker (the dinucleotide TC),
and the universal bacterial primer 8F (denoted in italics). The reverse primer,
59-CTATGCGCCTTGCCAGCCCGCTCAGNNNNNNNNCATGCTGCCT
CCCGTAGGAGT-39, was a composite of the 454 Titanium adapter B (under-
lined), a unique 8-base barcode (Ns), a linker (CA), and the broad-range bac-
terial primer 338R (in italics). DNA amplification was conducted at 958C for
15 minutes, followed by 34 cycles of 958C for 30 seconds, 528C for 30 sec-
onds, and 728C for 1 minute, with a final extension of 728C for 5 minutes.
PCR products were purified by using a QIAquick PCR Purification Kit
(Qiagen). Amplicons were quantified with the PicoGreen Assay (Invitrogen,
Life Technologies, Grand Island, NY) and diluted to 1 3 109 molecules/mL
in TE buffer. A sequencing library containing equimolar amounts of each
product was constructed for 454 FLX Titanium pyrosequencing (Roche,
Mannheim, Germany).Analysis of the 454 sequencing reads
All barcode-tagged sequence reads from the V1-V2 region of the 16S
rRNA genewere processed by using the QIIME pipeline.17 Sequences lacking
either the 59 and 39 primer sequences or those that contained 1 or more ambig-
uous bases were removed. All primer sequences were trimmed from the reads,
and any trimmed sequences shorter than 250 bp were removed. The sequences
were clustered into operational taxonomic units (OTUs) by using CD-HIT18
based on 97% sequence similarity and were taxonomically identified by using
RDP classifier19 with a minimum confidence score of 0.5. Chimeric sequenceswere identified and removed by using ChimeraSlayer and BlastFragment in
the QIIME pipeline. The Shannon index was calculated to estimate the a
diversity of each microbiota, and for b diversity analysis, unweighted UniFrac
or Bray-Curtis distance metrics were constructed with QIIME scripts.
Enterotype analysis was conducted by using the partitioning around
medoids clustering algorithm20 with a genus-level distance matrix that was
constructed with the Jensen-Shannon divergence algorithm.21 The Calinski-
Harabasz index was calculated to estimate the optimal number of enterotype
clusters, which was 2 for our data (Fig 1).
As an alternative approach to OTU construction based on CD-HIT,18
ESPRIT22 was used to sort the 454 sequencing reads into taxon-
independent OTUs that were grouped at various distance levels (equivalent
to identity levels of 90% to 97%). The OTU abundance matrix that was con-
structed with these OTUs was used to identify the most discriminatory OTUs
between the AD and non-AD microbiota by using the recursive feature elim-
ination support vector machine (RFE-SVM).23 OTUs that were not present in
at least 30% of the samples were removed from the data set to reduce the noise
level in the OTU data. Leave-one-out cross-validationwas used to estimate the
prediction accuracy for the AD microbiota from that of control subjects
without AD with the selected set of discriminatory OTUs.Whole-genome shotgun sequencing and sequence
analysis
The whole-genome sequences of 8 fecal samples (4 from patients with AD
and 4 from healthy subjects) were sequenced by using Illumina HiSeq2000
(Illumina, San Diego, Calif). A DNA library with a fragment length of
approximately 400 bp was prepared, and paired-end reads of 101 bp were
obtained from both ends. Sequence analysis was conducted with the CLC
Genomics Workbench (CLC bio, Aarhus, Denmark). Low-quality reads were
trimmed based on the following parameters: all sequences of less than the
quality score of 0.05 or with more than 2 ambiguous nucleotides. Sequences
shorter than 15 bp were also discarded. Functional profiles of the metagenome
were analyzed by using HUMAnN v0.99.24 All recently released Bacteroides
and Faecalibacterium genomes (bfg, bhl, bsa, bxy, bdo, bdh, bacc, fpr, and
fpa) were added to the KEGG Orthology (KO) database v54 for analysis.
We conducted a translated BLAST search of the Illumina reads against
the KO database by using USEARCH v8.025 under the following
conditions: (usearch_local command with –id 0.3 –evalue 1.0 –maxaccepts
20 –maxrejects 256). The results were passed through HUMAnN by using
default parameters. Then the normalized orthologous gene family abundances
were compared between the AD and non-AD groups.Pangenomic analysis of the 5 F prausnitzii strains
The genome sequences of the 5F prausnitzii strains were downloaded from
the Human Microbiome Project (HMP) Web site (http://www.hmpdacc.org/)
and compared to construct the pangenome. We compared all coding DNA
sequences (CDSs) from the strains by using BLASTP and clustered the related
CDSs into discrete orthologs based on both amino acid level similarity and
matching regions of 70% or greater. All CDSs from the 5 genomes were
annotated with the KO database26 based on the best BLASTP hits, with an
e-value cutoff of 1e-5.
The whole-metagenome reads from Illumina HiSeq2000 sequencing were
mapped on the genomes of the 5 F prausnitzii strains by using the CLC Geno-
mics Workbench (CLC bio) with the following settings: mismatch cost, 2;
insertion cost, 3; deletion cost, 3; length fraction, 0.5; similarity fraction,
0.8; auto detect paired distances, yes; global alignment, no; and nonspecific
match handling, map randomly. As a result, 10.14% of the Illumina reads
were mapped on the F prausnitzii genomes with 1.19% SE on average.Determination of SCFA levels in fecal samples
Fecal samples were homogenized in liquid nitrogen with a mortar and
pestle, and approximately 0.1 g of the crushed samples was transferred to
2-mL microfuge tubes. An internal standard (60 mL of 0.25 mmol/L
4-methylvaleric acid) was added to a tube containing a crushed fecal sample
FIG 1. Diversity profiles of the gut microbiota. A, Box plots of a diversity (internal diversity) in each
microbiota comparing patients with AD and control subjects without AD. B, b-Diversity among samples.
C, Enterotype patterns. D, Bacterial genera that are distinctive between the AD and non-AD microbiota.
*P < .05 and **P < .01.
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with 20 mL of 33% HCl, 1 mL of diethyl ether was added, and the tube was
vortexed for 10 minutes. The diethyl ether layer was separated by means of
centrifugation and transferred to a new tube. A second diethyl ether extraction
procedure was conducted, and the diethyl ether phase from the 2 extractions
was combined. Sixty microliters of the extract and 20mL ofN-tert-butyldime-
thylsilyl-N-methyltrifluoroacetamide were mixed in a glass insert in a gas
chromatography autosampler vial and incubated for 2 hours at room temper-
ature. Gas chromatography–mass spectrometry was conducted by using the
prepared samples, as previously described.27 Ratios of D-lactate and L-lactate
were measured by using the Megazyme enzymatic kit (Megazyme, Wicklow,
Ireland). Frozen fecal samples (0.1 g) were dissolved in 1mL of 0.1mol/L trie-
thanolamine buffer (pH 9.15) and centrifuged at 14,000g for 10 minutes at
48C. The supernatant was precipitated with 6.1 N trichloroacetic acid (10%
final concentration) and centrifuged at 4500g for 20 minutes at 48C. Precipi-
tated supernatants were used to measure lactate levels, according to the man-
ufacturer’s instructions.Promoter activity analysis
To compare promoter activity of the butyryl CoA:acetate CoA-transferase
gene in the 5 sequenced F prausnitzii strains (FP2_20620 for strain L2-6,
FAEPRAA2165_01575 for strain A2-165, HMPREF9436_00973 for strain
KLE1255, FPR_29560 for strain SL3/3, and FAEPRAM212_02812 for strain
M21/2), a lacZY fusion was made to the synthesized promoter of each gene by
using the promoter probe vector pLKC481,28 and the plasmid constructs were
used to transform Escherichia coliDH5a.29 E coli strains containing different
pLKC481 constructs were grown in LB broth to mid-log phase (OD6005 0.7)
and incubated on ice for 20 minutes. Two milliliters of each culture washarvested by means of centrifugation at 48C for 10 minutes, and the pellets
were resuspended in Z buffer.29 b-Galactosidase activity, representing pro-
moter activity, was assayed with O-nitrophenyl-b-D-galactoside as the sub-
strate and expressed as Miller units calculated as follows:
1000 3 ðOD42021:753OD550Þ=ðTime of incubation ½in minutes3
Volume ½in milliliters 3 OD600Þ:
RESULTS
Diversity profiles of the AD microbiota
DNA representing the gut microbiota from 132 subjects,
including 90 patients with AD, was isolated from fecal samples,
and the V1-V2 regions in the 16S rRNA gene pool were amplified
and sequenced by using 454 technology. The sequence reads were
processed to clean low-quality sequences, resulting in an average
sequencing depth of 6604 reads per sample. No significant
difference was observed in the microbial diversity (a diversity)
of all AD microbiota compared with that of all non-AD micro-
biota (Fig 1, A). Likewise, the dissimilarity in composition
between the AD and non-AD microbiota (b diversity) was not
significant (Fig 1, B). Each of the microbiota can be assigned to
an enterotype based on the major bacteria groups, although enter-
otyping might not be as informative as first proposed.30,31 Never-
theless, the 132 microbiota were best clustered into 2 enterotypes,
Bacteroides and Prevotella types, but the AD microbiota did not
FIG 2. The phylogenetic tree of F prausnitzii OTUs. A, The F prausnitzii tree
consists of 7 clades based on the V1-V2 sequence of the 16S rRNA gene. B,
The OTUs belonging to F06 are significantly more enriched in the ADmicro-
biota than in the non-AD microbiota. C, Enrichment of the F06 OTUs in the
AD microbiota is observed across all age groups. Asterisks indicate signif-
icant differences: *P < .05 and ***P < .003.
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Together, these data show that global-scale changes are not signif-
icantly different between AD and non-AD microbiota. However,
we observed specific changes in some bacterial clades in subsets
of the 90 ADmicrobiota divided by age (Fig 1,D, and see Fig E1,
A, in this article’s Online Repository at www.jacionline.org).
Although there have been reports of bacterial clade enrichment
belonging to the family Enterobacteriaceae and decreases in
those belonging to Lactobacillus and Bifidobacterium species in
patients with AD,13,14 these patterns were not observed in our
data. Differences in the patients with AD (eg, race and diets)
might be responsible for the apparent discrepancy between previ-
ous reports and this study. In addition, at least some of the bacteria
reported as AD linked in previous studies might be the ones to
bloom often in the damaged gut environment and not necessarily
associated with AD.32 Bacteria that are significantly associated
with the AD microbiota can include those that have a pathogenic
role in patients with AD, or they might simply have a growth
advantage in the changed gut environment. Pathogenic bacteria
that play a pivotal role in patients with AD can be specific,
possibly a single species or a consortium of a few bacteria,32
and their levels can be increased under all chronic AD conditions.
By contrast, those that are simply benefited by the disease might
involve diverse bacteria. As a whole, their levels might be
increased in all ADmicrobiota; however, individually, they might
not be present in all AD conditions.32 Considering these patterns,
most bacterial clades increased in the AD microbiota (Fig 1 and
see Fig E1) appear to be species simply taking advantage of
growth conditions in the guts of patients with AD. However, it
is possible that even if there were specific bacteria associated
with all ADmicrobiota, their small numbers were difficult to tease
out because of the overwhelming presence of other species pre-
sent within the same clade.
We conducted a RFE-SVM analysis33 to select for the top
discriminatory OTUs that are distinctive between AD and non-
AD microbiota. For this analysis, we used the OTUs constructed
by using ESPRIT, which is based on taxonomy-independent hier-
archical classification (at the 0.03 distance level, which generally
matches the species level).22 Half of the random selection from
the data was used as a training set for the RFE-SVM analysis to
select for discriminatory OTUs. The other half of the data were
used to test these OTUs for differentiating AD status. The
OTUs showed an accuracy of 88.14% on average, whereas the
control run with random OTUs showed an accuracy of 79.92%
on average (see Fig E2, A, in this article’s Online Repository at
www.jacionline.org). We found that many of the top discrimina-
tory OTUs belong to a few bacterial clades, some of which are
common to all ages (see Fig E2, B). Faecalibacterium species
is of particular interest because it was also shown to be signifi-
cantly increased in AD microbiota (Fig 1) and represents only a
single known species, F prausnitzii, although this species can
be divided into different phylogroups with possible physiologic
differences.34AD-specific subspecies of F prausnitzii OTUs
Because F prausnitzii was distinctly altered in the AD micro-
biota (Fig 1, A), was one of the most significant species in the
RFE-SVM model (see Fig E2), and is one of the most abundant
species in the human gut microbiota, suggesting its crucial
role in general human physiology,35 the evidence suggests thepossibility that F prausnitzii plays a pivotal role in patients with
AD. Furthermore, because F prausnitzii is a single species, it is
easier to study the composition of the clade. To explore the
possible presence of subspecies more associated with AD than
the species as a whole, we explored F prausnitzii OTUs. The
results show that the ESPRIT OTUs annotated as F prausnitzii
were clustered into 7 distinct clades in the phylogenetic tree
(Fig 2, A). This tree is based on V1-V2 sequence identity, and
therefore there is a possibility that each clade can be further
divided when the entire sequence of the 16S rRNA gene is
used. Nevertheless, we found that one of the clades, F06, was
significantly enriched in the AD microbiota (Fig 2, A and B).
Enrichment of the F06 OTUs in the AD microbiota was common
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old; Fig 2, C). This is intriguing because AD often occurs within
the first year of life,1 and this enrichment pattern suggests the pos-
sibility that F prausnitzii subspecies might play a role in the onset
of the disease.
Five strains of F prausnitzii, A2-165, M21/2, L2-6, S3L/3, and
KLE1255, have been sequenced through the HMP.36 The 16S
rRNA gene sequence of one of these strains, L2-6, has a unique
signature in the V1-V2 region, particularly in the V1 region,
which is distinctive from that of the other strains but closely
matches the F06 clade (see Fig E3, A, in this article’s Online
Repository at www.jacionline.org). Although the V1-V2 region
is only one part of the 16S rRNA gene, the almost perfect match
over this entire region (see Fig E3,B-D) suggests the close kinship
between L2-6 and F06 bacteria.
By conducting a cross-comparison of the predicted proteins
from all 15,825 genes in the 5 genomes with BLASTP (National
Center for Biotechnology Information, http://www.ncbi.nlm.nih.
gov), we determined the F prausnitzii pangenome was comprised
of 7,253 orthologous genes (see Fig E4, A, in this article’s Online
Repository at www.jacionline.org). The strain L2-6 had 855
unique genes, and the other strains had a similar number of unique
genes. A subset of 8 fecal samples (4 each of AD and non-AD
samples) were subjected to whole-genome shotgun sequencing
by using the Illumina HiSeq 2000 platform to compare the gut
microbiome contents in relation to the F prausnitzii pangenome,
generating sequence reads at an average depth of 552Mb per sam-
ple. These 8 fecal samples were chosen based on similar and high
F prausnitzii content (19% to 36%; see Table E2 in this article’s
Online Repository at www.jacionline.org). When the Illumina
reads were mapped to the F prausnitzii pangenome, most
(87.4%) of the genes unique to L2-6 had significantly higher
matches to the reads from the AD metagenome than those from
the subjects without AD (see Fig E4, B and Table E3 in this
article’s Online Repository at www.jacionline.org). In contrast,
the unique genes of A2-165 and KLE1255 had significantly
more matched reads from the non-AD metagenome (see Fig
E4, B). Together, these data suggest that organisms belonging
to clade F06 and the strain L2-6 are not only related at the V1-
V2 region of the 16S rRNA gene but also at the genomic level,
further supporting their close kinship. Such a connection between
phylogenetic information and genomic content in bacteria is due
to shared evolutionary history, which has previously been
observed and discussed.37Metabolic functions affected in the AD microbiome
We explored metabolic dysfunction of the ADmicrobiome in 2
ways, first by mapping the Illumina reads to the F prausnitzii
pangenome as the reference and second by mapping the same
Illumina reads to the KO database (see the Methods section).
The F prausnitzii pangenome approach of metagenomic analysis
is effective because there is high F prausnitzii content (19% to
36%) in the metagenome (see Table E2). Although this pange-
nome is based on only 5 strains, it includes 2 biologically signif-
icant strains: A2-165, a lack of which is associated with Crohn
disease,28 and L2-6, levels of which were significantly increased
in the AD microbiome, as shown in this study (see Figs E3 and
E4). To interpret the mapped data in terms of metabolic function,
the F prausnitzii pangenomewas annotated by using the KO data-
base, and the KOs with significantly (P < .05) different numbersof matching Illumina reads between the AD and non-AD micro-
biomes were collected. A total of 1332 KOs were assigned to the
pangenome, and 415 of these showed significant imbalances; 122
KOs were enriched in the ADmicrobiome, and 293 KOs were en-
riched in the non-AD microbiome (Fig 3, A, and see Table E4 in
this article’s Online Repository at www.jacionline.org).
The KOs that were significantly increased in the AD micro-
biome included those encodingmetabolic functions and pathways
responsive to oxidative stress (peroxiredoxin, dimethyl sulfoxide
reductase, and sufBC operon),38-40 various transition metal trans-
porters (Fe, Ni, Zn, and Mn) that might counteract nutrient metal
restriction exerted by the host,41 and those involved in use of a
major mucin component, N-acetylgalactosamine (GalNAc; a
phosphotransferase (PTS) system for uptake and catabolic en-
zymes; Fig 3, B).42 In contrast, genes with decreased content in
the AD microbiome included those involved in the biosynthesis
of various amino acids, nucleotides, peptidoglycans, and cofac-
tors (cobalamin, coenzyme A, and thiamine; Fig 3, A). Together,
the gene abundance profiles in the AD microbiome might reflect
the gut environment, with tissue damage resulting from increased
inflammation in the gut epithelium. The damaged gut environ-
ment might have increased levels of host-derived general nutri-
ents, such as amino acids, cofactors, and coenzymes, as well as
specific nutrients, including the mucin component GalNAc,42
the use of which requires specificmachinery for uptake and catab-
olism (Fig 3, B). The increased supply of additional nutrients
might result in the microbiome-wide loss of basic biosynthetic
gene content, whereas the presence of specific nutrients, such as
GalNAc, can apply selective pressure for auxotrophic specialists
or pathobionts that are capable of using them. Such a gut environ-
ment might in turn lead to further gut epithelial tissue breakdown,
completing the circle to cause dysbiosis of the gut microbiota
and thereby microbial dysfunction. It is intriguing to note that
among the 5 F prausnitzii reference strains, only L2-6 contains
the gene cluster for GalNAc use (Fig 3, B). In E coli O157:H7 a
PTS system for GalNAc uptake was shown to be required for
the bacterium to colonize the bovine gut epithelium.43
From the second analysis using the KO database to map the
Illumina reads, 122 of 5832 KOs showed significant differences
between the AD and non-AD metagenomes (see Fig E5 and
Table E5 in this article’s Online Repository at www.jacionline.
org). Levels of a total of 66 and 56 KOs were significantly
increased in the AD and non-AD metagenome, respectively.
Although the resolution of the KO analysis was lower than that
of the F prausnitzii pangenomic analysis, the KO analysis pro-
vides value because it includes more metagenome-level activity
beyond that of just the F prausnitzii component. Consistent
with the F prausnitzii pangenomic analysis, the KO analysis
showed the same pattern of increases in metal transporters,
GalNAc use, and oxidative stress modulation and decreases in
the biosynthesis of amino acids, nucleotides, and cofactors in
the ADmetagenome (see Fig E5). However, therewere new genes
that were found to be increased in the AD metagenome, such as
those encoding L-fucose use (L-fuculokinase and L-fucose isom-
erase). L-fucose is released from mucin glycoproteins and serves
as a major nutrient component in mucin other than GalNAc for
many gut bacteria, including Bacteroides thetaiotaomicron.44
More new genes include those encoding the glutathione S-trans-
ferase family, glucose-6-phosphate 1-dehydrogenase, glutamate
decarboxylase, and glyoxylate and dicarboxylate metabolism
(see Fig E5). Glutathione is a tripeptide of cysteine and glutamate,
FIG 3. F prausnitzii pangenomic genes that are significantly altered in the AD microbiome. A, Heat map of
significantly altered functions in the AD microbiome. KOs from the F prausnitzii pangenome that exhibit a
shift in abundance profile between the AD and non-AD microbiomes are shown. Relative abundance of the
matching Illumina sequence reads to a given KO is displayed as a log2 ratio. For some groups of KOs, mod-
ule (M) or pathway (ko) numbers are also shown. The presence of KOs in each F prausnitzii strain is also
shown. B, The gene cluster encoding GalNAc use that is uniquely present in the L2-6 strain among the
F prausnitzii strains. The GalNAc PTS system and the catabolic pathway encoded by the gene cluster are
also shown.
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stress caused by highly reactive oxygen and nitrogen metabo-
lites produced during inflammatory cascades.45 Glutathione-
S-transferases catalyze conjugation of the reduced form ofglutathione to endogenous compounds, such as peroxidized
lipids, for the purpose of detoxification. Glucose-6-phosphate
1-dehydrogenase levels have been shown to be increased in
E coli under oxidative stress, leading to increases in antioxidant
FIG 4. Analyses of SCFAs in fecal samples. A, Gas chromatographic–mass
spectrometric quantification of selected SCFAs in AD and non-AD fecal
samples. *P < .05. B, Comparison of butyryl CoA:acetate CoA-transferase
gene promoter activity from F prausnitzii strains.
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phosphate.46 Glutamate decarboxylase has been shown to play
an important role in antioxidation in E coli O157:H7 and Saccha-
romyces cerevisiae.47,48 In addition, glyoxylate and dicarboxylate
metabolism was shown to be involved in the antioxidation pro-
cess.49 Together, this abundance pattern of the genes augments
the notion that the AD gut epithelium has tissue damage resulting
from increased inflammation, as suggested by the F prausnitzii
pangenomic analysis (Fig 3).
Because levels of a variety of auxotrophs or pathobionts were
expected to be increased, the distribution of the gene family
coding for the GalNAc-specific IIA component in the PTS system
(agaF, K02744), one of the key genes in the cluster, was examined
in the ADmicrobiome, and extensive diversity was observed (see
Fig E6 in this article’s Online Repository at www.jacionline.org).
Cross-species enrichment of the genetic capacity for mucin
component use, although the actual activity or function of each
gene remains to be verified, suggests that the AD gut environment
is a favorable milieu for the establishment of a variety of auxo-
trophs and pathobionts other than the L2-6 strain, which might
have implications for the exacerbation and chronic nature of AD.F prausnitzii F06 subspecies blooms might lead to a
reduction in butyrate and propionate production
Production of SCFAs by the gut microbiota has tremendous
health benefits.50,51 To compare the production of these metabo-
lites between the AD and non-ADmicrobiome, we conducted gas
chromatographic–mass spectrometric analyses on fecal samples
(Fig 4, A). Levels of major SCFAs, acetate, propionate, butyrate,
and D- and L-lactate were measured and compared between
paired AD and non-AD fecal samples that were selected forsimilarly in high total F prausnitzii levels but also with significant
differences in F06OTU levels (Fig 4,A). Because the total level of
F prausnitzii in these samples was much higher than levels of
other SCFA producers, including Eubacterium rectale, Eubacte-
rium hallii, and Roseburia species (see Table E6 in this article’s
Online Repository at www.jacionline.org), the assay results could
be directly linked to changes in F prausnitzii composition.
Comparative analysis of the 12 pairs of samples showed that
the low F06 microbiome samples had more butyrate and propio-
nate than the paired high F06 microbiome samples (Fig 4, A).
Such a major change in SCFA concentration and ratio in the pa-
tients with AD compared with the subjects without AD is signif-
icant because it suggests major differences in the gut environment
between the 2 groups. Additional differences between the AD and
non-AD groups, including age in some pairs, did not seriously
affect the SCFA profiles, suggesting that the F06 level is the
most important contributing factor determining the SCFA profile.
It is noteworthy that propionate was recently shown to have an
antiallergic effect; it impaired the capacity of dendritic cells to
provoke TH2 cell–mediated allergic airway inflammation.
51 On
the other hand, there were no significant differences in acetate
levels, total lactate levels, or the ratio between L- and D-lactate
levels, which was previously shown to be associated with disor-
ders (Fig 4, A).50 Although changes in SCFAs are a likely mech-
anism for the proposed effects of F prausnitzii subspecies,
additional anti-inflammatory agents that can be produced by
F prausnitzii also remain to be explored.
Because the L2-6 strain, which is related to the F06 clade, and
the other 4 strains have the same butyrate biosynthesis pathway
(see Fig E7 in this article’s Online Repository at www.jacionline.
org), we investigated whether a difference in the expression of the
pathway, particularly the gene coding for the key enzyme butyryl
CoA:acetate CoA-transferase, could be detected. The promoter
region of this gene from each strain was synthesized and cloned
into a promoter-probe vector28 upstream of the lacZ reporter
gene, and gene expression was compared in E coli (Fig 4, B).
Although the assay was not conducted in the natural F prausnitzii
host, the basic strength of the promoters could be compared
among strains because any regulatory function that is not properly
operational in E coli would be equally applied to the promoters.
The results show that the promoter from the A2-165 strain is
significantly stronger than the promoters from L2-6 and other
strains (Fig 4, B). In fact, these data are consistent with a concor-
dant result that showed differential butyrate production in the
A2-165 and L2-6 strains,52 although the same pattern was not
observed when a different growth medium was used.53 Together,
these data suggest that different butyrate levels in fecal samples
might be largely attributable to different F prausnitzii subspecies
composition. We conclude that dysbiosis in the F prausnitzii spe-
cies in association with AD might result in suppression of high
butyrate producer subspecies, such as the A2-165 type bacteria,
which might lead to a reduction in overall butyrate production.DISCUSSION
A dominant human intestinal bacterial species, F prausnitzii,
has been considered beneficial to gut health through its pro-
duction of SCFAs, in particular butyrate, which has anti-
inflammatory effects and also serves as a direct source of energy
for the gut epithelium.35,54 Decreased overall levels ofF prausnit-
zii and accompanied reduction in SCFA production have been
FIG 5. Proposed model of AD in association with dysfunction of F prausnit-
zii. Damaged intestinal mucosa at sites of increased inflammation can
release a variety of nutrients, including the core mucin component GalNAc,
which stimulates the growth of L2-6–type bacteria and other auxotrophic
opportunists. The bloom of poor butyrate producers, such as L2-6–type
bacteria, in the F prausnitzii populationmight lead to a decrease in the num-
ber of high butyrate producers, such as A2-165–type bacteria. This intraspe-
cies compositional change results in decreased production of butyrate and
propionate, which in turn leads to further dysregulation of gut epithelial
inflammation, establishing feedback interactions. It is this feedback loop
that underlies the onset and chronic progression of AD by maintaining
increased permeability in the gut epithelium, which can lead to aberrant
TH2-type immune responses in the skin.
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study, it is evident that the balance among the subspecies
of F prausnitzii, specifically that between the L2-6– and
A2-165–type bacteria, can also result in changes in SCFA produc-
tion (Fig 5). This study also demonstrates the importance of
fine-level characterization of bacterial species to understand the
function of the microbiome, which is affected by interactions
among closely related bacteria that might compete for the same
niche but have distinct activities.
The AD metagenomic data revealed increased numbers of
genes encoding use of the major mucin components GalNAc and
L-fucose and various nutrients that would be released generally
from damaged gut epithelial cells (Figs 3 and 5), which might
reflect the increased inflammation in the gut epithelium and corre-
spond in a broad sense to ‘‘leaky gut syndrome.’’7 When such
epithelial damage occurs, possibly triggered by dysbiosis in
F prausnitzii or by some other unknown causes, this might in
turn lead to dysbiosis in F prausnitzii, resulting in a bloom of
various pathobionts or auxotrophs and establishing a feedback
loop between dysbiosis in F prausnitzii and dysregulation of
gut epithelial inflammation. Epithelial damage has been associ-
ated with atopic eczema and many diseases, including celiac dis-
ease, alcoholism, Crohn disease, chronic giardiasis, and intestinal
candidosis.7 The damaged epithelium with increased perme-
ability might allow for the passage of undigested foods, toxins,
and pathogenic microbes into the systemic circulation, ultimatelyallowing harmful substances to reach the skin (Fig 5).9,55
Although much of the humoral process needs to be explored,
studies suggest that the aberrant TH2-type immune responses
might react to these foreign substances by releasing proinflamma-
tory cytokines, thus increasing inflammation in the deep layers of
the skin and causing damage (Fig 5).5,56 Numerous studies report-
ing the positive effects of probiotics and prebiotics on the diges-
tive tract in reinforcing a healthy immune system support the
pivotal role played by the gut microbiota in the onset and progres-
sion of many diseases.57,58 Our data suggest that the development
of methods to target F prausnitzii, the dysfunction of which
underlies chronic AD, might hold the key to effective diagnosis
of and therapy for AD.
Clinical implications: Our results provide the insights into the
basis of AD originated in the gut microbiome, which will lead
to the development of effective diagnosis of and therapy for
the disease.REFERENCES
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